Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neoplasms 7Breast Neoplasms 7Head and Neck Neoplasms 5Glioblastoma 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Melanoma 3Hematologic Neoplasms 3Glioma 3Uterine Cervical Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Lymphedema 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematopoietic and Lymphatic System Neoplasm 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Astrocytoma 2Xeroderma Pigmentosum 1Triple Negative Breast Neoplasms 1Trichothiodystrophy Syndromes 1Tongue Neoplasms 1Spinal Cord Neoplasms 1Smoking Cessation 1Smoking 1Signs and Symptoms, Digestive 1Sexuality 1Sexual Dysfunction, Physiological 1Rectal Neoplasms 1

Interventions

lenvatinib 2temsirolimus 1penpulimab 1cabozantinib 1anlotinib 1Vinorelbine 1Temozolomide 1Sirolimus 1Restraint, Physical 1Everolimus 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Paraganglioma, Extra-Adrenal × Restraint, Physical × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡